Clinical Trials - April 26, 2021
Green light for Oasmia’s phase 1b Docetaxel Micellar trial
Oasmia Pharmaceutical has announced that Swissmedic and Swissethics approval has been received to initiate a Phase 1b clinical trial with the Swiss Group for Clinical Cancer Research (SAKK) of Oasmia’s Docetaxel micellar in patients with advanced prostate cancer. Trial initiation is expected to commence in the first half of 2021, states the company in a […]
In a new job - April 3, 2021
Oasmia appoints new Chief Scientific Officer
Oasmia Pharmaceutical has announced the appointment of Reinhard Koenig as Chief Scientific Officer with immediate effect. Koenig is an experienced executive with over 25 years’ experience at life-science companies, many of them operating internationally, states the company in a press release. He has a deep understanding of successful product development and commercialization of medicines in […]
New Market - January 19, 2021
Oasmia secures IP rights in Australia and Brazil
The XMeNa patent protects an improved method for producing Oasmia’s nanotechnology platform XR-17, a drug-delivery system currently used with paclitaxel and other cancer drugs. The patent is important for Oasmia as it expands the territories for exclusivity of the key technology XR‑17 used in our lead product Apealea (paclitaxel micellar), which is being launched in […]
Clinical Trials - March 30, 2016
Oasmia enrolls first patient in Docecal study
Oasmia Pharmaceutical, a developer of drugs within human and veterinary oncology, announces that the first patient has been enrolled in the Phase I clinical study of the company’s cancer treatment candidate Docecal, to be performed internationally. Docecal was approved for clinical trials in December, 2015. Docecal is a nanoparticle and water-soluble formulation of docetaxel, one […]
Drug Development Pharma - February 5, 2016
Oasmia apply for marketing authorization
Oasmia Pharmaceutical has announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for its lead cancer product Apealea (also known as Paclical). Apealea is a novel formulation of paclitaxel based on the patented excipient platform XR-17, which forms Cremophor®-free micellar nanoparticles with paclitaxel. The indication sought for Apealea is treatment […]
New Market - January 5, 2016
Oasmia applies for market approval in Russia
Swedish Oasmia Pharmaceutical has submitted an application for marketing approval of Doxophos for Russia and the Commonwealth of the Independent States (CIS). The company expects market approval of Doxophos by the end of 2016. Doxophos is a hybrid and novel nanoparticle formulation of one of the most commonly used anti-cancer substances in the world, doxorubicin. […]
